The discovery that mutations in BRAF resulting in constitutive kinase activation are common occurrences in solid tumours (Davies et al, 2002) led a number of groups to analyse thyroid cancers for similar mutations in BRAF. This evidence concerns the gene BRAF and thyroid cancer.